Moderna (MRNA) Stock Surges On Coronavirus Vaccine Testing

Moderna MRNA Stock News

Moderna Inc (NASDAQ: MRNA) is surging in the market this morning, trading on gains of more than 15%. The gains come after the company announced that it is sending the first coronavirus vaccine into clinical trials. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

MRNA Stock Surges On Coronavirus Vaccine News

In the press release, Moderna said that it has released the first batch of mRNA-1273. This is the company’s vaccine candidate developed to fight against the novel coronavirus.

In the release, MRNA said that viles of the vaccine have been shipped to the National Institute of Allergy and Infectious Disease to be used in a planned Phase 1 study in the United States.

The vaccine is encoded for a prefusion stabilized form of the Spike (S) protein. It was selected by Moderna in collaboration with investigators at the NIAID Vaccine Research Center. Moreover, the funding for the manufacturing of this batch of vaccine was funded by the Coalition for Epidemic Preparedness Innovations.

In a statement, Juan Andres, Chief Technical Operations and Quality Officer at MRNA, had the following to offer:

I want to thank the entire Moderna team for their extraordinary effort in responding to this global health emergency with record speed. The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification. This would not have been possible without our Norwood manufacturing site, which uses leading-edge technology to enable flexible operations and ensure high quality standards are met for clinical-grade material.

This Is Huge News

There’s no doubt that the news here is huge. Think about it, the Wuhan Coronavirus has been at the top of headlines for some time now. As the virus continues to spread throughout China, Italy, and other areas around the world, the demand for a vaccine is only growing.

This has led to several biotechnology companies, including Moderna, to race to come up with an effective vaccine against the illness. While several companies are in the race, MRNA is the first to push their vaccine to human trials.

You know what they say. The early bird gets the worm.

If these trials go well, the company may become the first to put a vaccine on the market. This would generate tremendous revenue ahead.

While MRNA has the vaccine in testing, there are other stocks that may benefit here. In particular, iBio (NASDAQ: IBIO) is at the top of the list for those to benefit from a vaccine. This is because the company’s FastPharming Facility has the ability to manufacture vaccines incredibly quickly, making it a perfect partner for getting something like this out to the world.

So, not only is this good news for MRNA, IBIO investors should be watching closely as this may become great news for them as well.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.